The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 02, 2021
Filed:
Jan. 12, 2017
Waseda University, Shinjuku-ku, JP;
Kabushiki Kaisha Yakult Honsha, Minato-ku, JP;
Yoichi Nakao, Shinjuku-ku, JP;
Shigetaka Asano, Shinjuku-ku, JP;
Daisuke Arai, Shinjuku-ku, JP;
Yukari Kase, Shinjuku-ku, JP;
Teppei Shimomoto, Shinjuku-ku, JP;
WASEDA UNIVERSITY, Shinjuku-ku, JP;
KABUSHIKI KAISHA YAKULT HONSHA, Minato-ku, JP;
Abstract
Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.